Koiti Inokuchi

Nippon Medical School — Japan

Medicine · Health Sciences

35h-index3.9kcitations262works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(84), Acute Myeloid Leukemia Research(76), Chronic Lymphocytic Leukemia Research(61), Eosinophilic Disorders and Syndromes(35), Multiple Myeloma Research and Treatments(32)

Publications262 total

Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor <i>BCR-ABL</i> (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Japanese Journal of Clinical Oncology·2023· 2 citedOpen Access
Supplementary information from Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells
2023Open Access
Data from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
2023Open Access
Supplementary Tables S1 to S5 and Supplemental Figures 1 to 15 from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
2023Open Access
Supplementary Table 1 and Supplementary Figures 1 through 3 from Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
2023Open Access
Supplementary Table 1 and Supplementary Figures 1 through 3 from Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
2023Open Access
Data from Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells
2023Open Access
Supplementary Tables S1 to S5 and Supplemental Figures 1 to 15 from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
2023Open Access
Data from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
2023Open Access
Data from Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells
2023Open Access
Data from Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
2023Open Access
Supplementary information from Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells
2023Open Access
Data from Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
2023Open Access
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma
Experimental Hematology·2023· 3 citedOpen Access
Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
International Journal of Hematology·2023· 7 citedOpen Access
Safety and efficacy of high‐dose cytarabine MEAM therapy and other treatments for auto‐peripheral blood stem cell transplantation: A retrospective comparative study
Asia-Pacific Journal of Clinical Oncology·2022· 3 cited
Cyclophosphamide‐induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less
Asia-Pacific Journal of Clinical Oncology·2022· 21 cited
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
The Lancet Haematology·2021· 60 cited
Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial
Blood·2021· 2 cited
Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial
Blood·2021· 1 cited
page 1 of 14Next →

Frequent Co-authors

Hiroki Yamaguchi(23), Satoshi Wakita(13), K Dan(9), Kensuke Usuki(8), Shunsuke Yui(8), Kazuo Dan(8), Takashi Kumagai(8), Chikashi Yoshida(8), Kenji Tajika(7), Saiko Kurosawa(7), Ikuko Omori(7), Tomoaki Kitano(7), Junichi Sakamoto(7), Masahiro Sakaguchi(6), Seiji Gomi(6), Atsushi Marumo(6), Yusuke Fujiwara(6), Kazuteru Ohashi(6), Takahiro Fukuda(6), Satoshi Morita(6)